Exagen AI Stock Analysis
Exagen (E08A) AI Stock Analysis
Exagen
(Frankfurt:E08A)
No summary available
Exagen (E08A) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 96.95M
- Dividend Yield
- ―
- Average Volume (3M)
- 111
- Price to Earnings (P/E)
- -5.0
- Beta (1Y)
- 0.96
- Revenue Growth
- 8.32%
- EPS Growth
- 22.28%
- Country
- Germany
- Employees
- 216
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Exagen Business Overview & Revenue Model
Company Description
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheu...
Exagen Earnings Call Summary
The call was strongly positive, with record quarterly revenue, double-digit year-to-date revenue growth, improving adjusted EBITDA, rising ASP, expanding commercial productivity, strong Pharma Services growth, balance sheet strengthening and meaningful progress toward the myositis launch. The principal challenges were modest third-quarter volume growth, normal seasonal effects, continued adjusted EBITDA losses, uncertain PAMA implementation and no update on the AVISE CTD LCD. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Exagen reiterated 2026 full year revenue guidance of $72 million to $75 million, assuming high single-digit volume growth and mid-single-digit full year ASP growth compared to the fourth quarter 2025 exit rate, with typical second half volume seasonality and a growing contribution from Pharma Services; management also expects high single digits volume growth, low to mid-single digits ASP growth and revenue growth in the double digits on an annual basis, targets an ASP of at least 50% of Medicare reimbursement or approximately $600 to $650 per test over time, expects gross margin to progress to the mid-60s over time, and believes that at $80 million and around a 60% gross margin it should be right at breakeven on an adjusted EBITDA basis; the myositis offering is on track for launch in early '27, with the validation package expected by the end of January, while potential PAMA impact is expected to be low single-digit impact if it were to be realized fully.
Exagen Risk Analysis
Exagen disclosed 73 risk factors in its most recent earnings report. Exagen reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksExagen Peers Comparison
Overall Rating
SERA54Neutral
ACRS48Neutral
PRE48Neutral
MDXH40Underperform
STIM40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | $75.16M | -2.82 | -52.54% | ― | 1.05% | 13.67% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $555.14M | -6.03 | -59.20% | ― | -59.34% | 57.30% | |
| 48Neutral | $174.63M | -2.03 | -74.79% | ― | 176.11% | -39.52% | |
| 40Underperform | $11.20M | -0.11 | 306.18% | ― | 3.67% | -19.54% | |
| 40Underperform | $96.38M | -3.85 | -127.86% | ― | 23.01% | 60.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:E08A | Exagen | 3.54 | -2.96 | -45.54% | |
| ACRS | Aclaris Therapeutics Inc. | 3.50 | 0.75 | 27.27% | |
| MDXH | Mdxhealth S.A. | 0.12 | -3.45 | -96.72% | |
| STIM | Neuronetics | 1.24 | -0.03 | -2.36% | |
| PRE | Prenetics Group Limited | 10.31 | -3.79 | -26.88% | |
| SERA | Sera Prognostics, Inc. | 1.89 | -1.49 | -44.08% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
